LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Schrodinger Inc

Suletud

SektorTervishoid

23.59 0.9

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

22.95

Max

23.67

Põhinäitajad

By Trading Economics

Sissetulek

-20M

-60M

Müük

-29M

60M

Aktsiakasum

-0.64

Kasumimarginaal

-100.432

Töötajad

891

EBITDA

-32M

-51M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+40.03% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

30. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

193M

1.8B

Eelmine avamishind

22.69

Eelmine sulgemishind

23.59

Uudiste sentiment

By Acuity

37%

63%

124 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Schrodinger Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. nov 2024, 11:55 UTC

Peamised uudised

Schrödinger's Stock Soars 9% As It Enters Collaboration Pact With Novartis For Up To About $2.5 Billion In Payments -- MarketWatch

Võrdlus sarnastega

Hinnamuutus

Schrodinger Inc Prognoos

Hinnasiht

By TipRanks

40.03% tõus

12 kuu keskmine prognoos

Keskmine 32.71 USD  40.03%

Kõrge 45 USD

Madal 26 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Schrodinger Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

6

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

23.27 / 26.13Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Very Strong Bullish Evidence

Pikk perspektiiv

Very Strong Bullish Evidence

Sentiment

By Acuity

124 / 382 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.